Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

nilotinib 6bosutinib 4asciminib 3Imatinib Mesylate 3Decitabine 3decitabine and cedazuridine drug combination 2cedazuridine 2avapritinib 2Dasatinib 2Cytarabine 2Azacitidine 2treosulfan 1trametinib 1tagraxofusp 1pemigatinib 1olutasidenib 1luspatercept 1ivosidenib 1imetelstat 1glasdegib 1enasidenib 1dabrafenib 1GRN163L peptide 1Emapalumab 1Daunorubicin 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × olutasidenib × Myeloid × Clear all
NCT02719574 2025-06-26

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
336 enrolled 48 charts 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡